Clinical Trial Update: A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update concerns TAK-861 for central hypersomnia, specifically Narcolepsy Type 1, across Phase 2 and Phase 3, and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy Type

Drugs mentioned

• TAK-861

Snippet

Sponsor: Takeda | Conditions: Narcolepsy Type 1 | Phase 2, Phase 3 | Status: RECRUITING